<DOC>
	<DOCNO>NCT01913067</DOCNO>
	<brief_summary>A phase II trial evaluate Cabazitaxel patient brain metastasis secondary breast non-small-cell lung cancer ( NSCLC ) . OBJECTIVES : Primary : The purpose study determine cabazitaxel induce reduction size brain metastasis metastatic HER2-negative breast cancer NSCLC brain metastasis previously treat whole brain irradiation require immediate brain irradiation . Secondary : - To determine effect cabazitaxel time initiate whole brain irradiation radiosurgery - To determine effect cabazitaxel time develop neurological symptom - To determine effect cabazitaxel time disease progression brain - To determine effect cabazitaxel time disease progression outside brain . This evaluate separately breast NSCLC cohort To determine objective extra-cranial response ( applicable ) . This evaluate separately breast NSCLC cohorts - To determine safety cabazitaxel</brief_summary>
	<brief_title>Evaluation Cabazitaxel Patients With Brain Metastasis Secondary Breast Cancer NSCLC</brief_title>
	<detailed_description>This single arm , prospective trial use 2-stage Simon design , eligible patient receive intravenous cabazitaxel two cycle follow response evaluation . Based pre-specified criterion response ( intra-cranial , patient allow continue study drug .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 , ECOG 01 Histologically confirm 1 ) HER2negative invasive breast carcinoma 2 ) NSCLC In patient breast cancer , HER2negative status FISH immunohistochemistry ( score 0 , +1 ) . In patient breast cancer , know estrogen progesterone receptor status . Evidence measurable disease brain ( least 1cm ) Stable decrease dosage steroid 7 day prior baseline MRI . No evidence ( cortical ) cognitive impairment define MiniMental Status Exam ( MMSE ) score ≥ 25/30 . No 4 prior line systemic chemotherapy metastatic setting Adequate hematopoietic function define : Hemoglobin ≥ 9.0g/dL Absolute neutrophilic count ≥ 1.5 x 109L Platelet count ≥ 100 x 109L Adequate hepatic function define : AST ≤ 2.5 x upper limit normal ( ULN ) ALT ≤ 2.5 x ULN Total bilirubin ≤ 1.0 x ULN Adequate renal function define serum creatinine ≤ 1.5 x ULN . If creatinine range 1.0 1.5 x ULN , creatinine clearance determine CKDEPI formula calculate patient clearance &gt; 60 mL/min eligible Adequate contraceptive method patient childbearing potential . History prior whole brain irradiation Progressive neurological symptom require immediate brain irradiation Pregnancy lactation History hypersensitivity reaction taxanes History hypersensitivity polysorbate 80 contain agent Current plan treatment strong inhibitor inducer cytochrome P450 . Less 3 week since last treatment chemotherapy , biological therapy , and/or immunotherapy Leptomeningeal carcinomatosis Contraindication contrastenhanced MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>brain metastasis</keyword>
	<keyword>breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>NSCLC</keyword>
</DOC>